Samantha Semenkow - Biotech Valuation in the Public Markets

Sam Semenkow, Ph.D. is a Director of Portfolio Intelligence at Bridge Bio, a unique biotechnology company that develops drugs in several modalities for a number of diverse disease areas. Prior to joining Bridge Bio, Sam was an Associate in the equity research group at Citi, a multinational bank. As an equity research associate, Sam covered a number of public biotech companies- applying valuations and building financial models for commercial and clinical stage drug candidates. Sam holds a Ph.D from the Johns Hopkins School of Medicine. In this episode, Sam discusses the hiring process for equity research groups for individuals with advanced degrees. She also describes the type of work one would do while working in equity research. We finish the episode with a description of Bridge Bio, and a discussion on assessing risk in biotech.Hosted by Roshan Chikarmane, Jenna Glatzer, and Joe Varriale.